Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Phospholipase A2s (PLA2) is a major component of snake venom with diverse pathologic toxicities and, therefore, a potential target for antivenom therapy. Varespladib was initially designed as an inhibitor of mammal PLA2s, and was recently repurposed to a broad-spectrum inhibitor of PLA2 in snake venom. To evaluate the protective abilities of varespladib to hemorrhage, myonecrosis, and systemic toxicities that are inflicted by different crude snake venoms, subcutaneous ecchymosis, muscle damage, and biochemical variation in serum enzymes derived from the envenomed mice were determined, respectively. Varespladib treatment showed a significant inhibitory effect to snake venom PLA2, which was estimated by IC50 in vitro and ED50 in vivo. In animal models, the severely hemorrhagic toxicity of D. acutus and A. halys venom was almost fully inhibited after administration of varespladib. Moreover, signs of edema in gastrocnemius muscle were remarkably attenuated by administration of varespladib, with a reduced loss of myonecrosis and desmin. Serum levels of creatine kinase, lactate dehydrogenase isoenzyme 1, aspartate transaminase, and alanine transaminase were down-regulated after treatment with varespladib, which indicated the protection to viscera injury. In conclusion, varespladib may be a potential first-line drug candidate in snakebite envenomation first aid or clinical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Snake Venom PLA 2 , a Promising Target for Broad-Spectrum Antivenom Drug Development
Xiao, H., Pan, H., Liao, K., Yang, M., & Huang, C. (2017) · BioMed Research International · doi:10.1155/2017/6592820 · Cited by 113 · cited 2×
“The reason was probably due to the lower PLA2 content in the two Elapid venoms [25].”
BackgroundSelf-citation
Cited by
Snake Antivenom: Challenges and Alternate Approaches
Alangode, A., Rajan, K., & Nair, B. G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114135 · Cited by 88
Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
“ANOVA statistics for individual statistically analysed graphs are: (b) F(5,24) = 1.”
Xie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020) · Biomedicines · doi:10.3390/biomedicines8060165 · Cited by 58
Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., et al. (2022) · Toxins · doi:10.3390/toxins15010022 · Cited by 39
Liu, J., Wang, L., Xie, M., Zhao, W., Sun, J., Jin, Y., Liu, M., Zhao, J., Cheng, L., Wen, C., et al. (2025) · Redox Report · doi:10.1080/13510002.2025.2507557 · Cited by 13
“Hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS) staining was conducted following established protocols [44–46].”
Self-citation
Metadata
- Authors
- Wang, Y., Zhang, J., Zhang, D., Xiao, H., Xiong, S., & Huang, C.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-02-12
- Volume
- 23
- Issue
- 2
- Pages
- 391
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2789669580
- Cited by
- 87
- References
- 1
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.